Sign Out
Not metabolize via CYP 450 enzymes and it is not likely to interact with co-mediations, inhibitors or inducers of these enzymes.
Concurrent use of antidiabetic agents and somatostatin analogues may result in impaired glucose regulation.
Concurrent use of fluoroquinolones and antidiabetic agents may result in changes in blood glucose and increased risk of hypoglycemia or hyperglycemia.
Concurrent use of hydroxychloroquine or chloroquine and antidiabetic agents may result in hypoglycemia.
Concurrent use of thioctic acid and antidiabetic agents may result in increased risk of hypoglycemia.
Concurrent use of antidiabetic agents and beta-adrenergic blockers may result in hypoglycemia or hyperglycemia; decreased symptoms of hypoglycemia.
Continue with Google